Protagonist Therapeutics (PTGX) Tax Provisions (2018 - 2026)

Protagonist Therapeutics (PTGX) has 7 years of Tax Provisions data on file, last reported at -$1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Tax Provisions changed N/A year-over-year to -$1.5 million; the trailing twelve-month figure through Mar 2026 stood at -$636000.0 (down 170.67% YoY), and the FY2025 full-year result was $838000.0, down 80.14% from the prior year.
• Tax Provisions declined to -$1.5 million in Q1 2026, from $666000.0 in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $3.3 million in Q1 2024 to a low of -$16.6 million in Q4 2023.
• A 4-year average of -$1.6 million and a median of -$110000.0 in 2024 frame the typical range for Tax Provisions.
• Peak annual rise in Tax Provisions reached 128.57% in 2025, while the deepest fall reached 67.03% in 2025.
• Tracing PTGX's Tax Provisions over 4 years: stood at -$16.6 million in 2023, then jumped by 112.18% to $2.0 million in 2024, then tumbled by 67.03% to $666000.0 in 2025, then tumbled by 325.53% to -$1.5 million in 2026.
• Business Quant data shows PTGX's Tax Provisions at -$1.5 million in Q1 2026, $666000.0 in Q4 2025, and $200000.0 in Q2 2025.